Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/06/06 08:42:16」(JST)

wiki en

Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010.^[1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt.

Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.^[2]

References

^ "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.
^ Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. シェーグレン症候群におけるドライアイの治療 treatment of dry eyes in sjogrens syndrome

English Journal

A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore.

Gong L1, Sun X1, Ma Z2, Wang Q3, Xu X4, Chen X5, Shao Y6, Yao K7, Tang L8, Gu Y9, Yuan H10, Chua WH11, Chuan JC12, Tong L13.
The British journal of ophthalmology.Br J Ophthalmol.2015 Jul;99(7):903-8. doi: 10.1136/bjophthalmol-2014-306084. Epub 2015 Jan 28.
AIMS: To compare the efficacy and safety of 3% diquafosol ophthalmic solution with those of 0.1% sodium hyaluronate ophthalmic solution in patients with dry eye in China and Singapore.METHODS: A total of 497 patients with dry eye (Schirmer's test, 5 mm; fluorescein and RB score, 3 points) from Chi
PMID 25631485

Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.

Yang JM1, Choi W, Kim N, Yoon KC.
Optometry and vision science : official publication of the American Academy of Optometry.Optom Vis Sci.2015 Jun 23. [Epub ahead of print]
PURPOSE: To compare the treatment effects of topical cyclosporine A (CsA) and diquafosol sodium (DQS) for the treatment of moderate to severe dry eye disease (DED).METHODS: This prospective, nonrandomized, comparative study involved 60 eyes of 60 patients with moderate to severe DED who were treated
PMID 26107023

Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials.

Wu D1, Chen WQ, Li R, Wang Y.
Cornea.Cornea.2015 Jun;34(6):644-50. doi: 10.1097/ICO.0000000000000429.
PURPOSE: To evaluate the efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye.METHODS: Randomized clinical trials (RCTs) from MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were identified to evaluate the efficacy and safety of topical
PMID 25909234

Japanese Journal

ムチンと水分を供給するジクアス点眼薬 (特集ドライアイの新しい治療)

山口昌彦,大橋裕一
あたらしい眼科 32(7), 935-942, 2015-07
NAID 40020552985

眼疲労を訴えるドライアイ患者に対するジクアス点眼液3%の有効性

吉田紳一郎,藤原慎太郎,松本佳浩 [他]
あたらしい眼科 32(6), 871-875, 2015-06
NAID 40020516962

点眼薬投与にてハードコンタクトレンズ装用可能になった高度ドライアイの1例

小林茂樹
日本医科大学医学会雑誌 11(1), 20-24, 2015
… Purpose:To report a case of severe dry eye associated with high myopia by combination therapy with diquafosol tetrasodium and sodium hyaluronate enabled the wearing of hard contact lenses (HCL) and improved symptoms.Case: The patient was a 76-year-old woman for whom sodium hyaluronate was prescribed because ophthalmic dryness and a foreign-body sensation made her unable to wear HCL. …
NAID 130004941836

Related Pictures

Diquafosol - Wikipedia, the free Diquafosol tetrasodium.svg Diquafosol vs Sodium Hyaluronate in Dry Diquafosol Beats Hyaluronate in Treating Che fine ha fatto il diquafosol 차 선택제로써의 디쿠아포솔의 Diquafosol works in an independent Diquafosol Tetrasodio(DIQUAS).Nuevo

★リンクテーブル★

リンク元

「ジクアホソル」

Diquafosol
Names
	IUPAC name [[[[(2R,3S,4R,5R)-5-(2,4-Dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
	Other names P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium
Identifiers
CAS Number	59985-21-6 ; 211427-08-6 (tetrasodium salt) ;
3D model (JSmol)	Interactive image;
ChemSpider	130647; 130646 (tetrasodium salt);
IUPHAR/BPS	1736;
PubChem CID	148197; 148196 (tetrasodium salt);
UNII	7828VC80FJ;
	InChI InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1 Key: NMLMACJWHPHKGR-NCOIDOBVSA-N ; InChI=1/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1 Key: NMLMACJWHPHKGR-NCOIDOBVBD ;
	SMILES O=C1\C=C/N(C(=O)N1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]4O[C@@H](N\3C(=O)NC(=O)/C=C/3)[C@H](O)[C@@H]4O ;
Properties
Chemical formula	C18H26N4O23P4
Molar mass	790.31 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

　　[★]

英: diquafosol
化: ジクアホソルナトリウム diquafosol sodium
商: ジクアス

[1] "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.

[2] Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.

匿名

検索

案内

案内

diquafosol